A Clinical Trial to Evaluate [14C]-MK-4208/[14C]-TERN-701 in Healthy Adult Male Participants (MK-4208-002/TERN701-1016)

This clinical trial, identified as MK-4208-002/TERN701-1016, aimed to evaluate the substances [14C]-MK-4208 and [14C]-TERN-701. Healthy adult male participants were enrolled in the study. The primary intervention involved the administration of the drug TERN-701. The objective was to investigate the effects and safety of these substances in the specified population. The study was sponsored by Terns, Inc., a subsidiary of Merck & Co., Inc., located in Rahway, New Jersey, USA. This clinical trial has been successfully completed.